Galaxy Digital Inc. Class A Common Stock vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Galaxy Digital Inc. Class A Common Stock trades at $17.5 (market cap $3.83B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 2.8× Galaxy Digital Inc. Class A Common Stock's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Galaxy Digital Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Galaxy Digital Inc. Class A Common Stock for 2 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| GLXY | RDY | |
|---|---|---|
Market Cap | $3.83B | $10.78B |
Volume | 5,859,599 | 2,724,343 |
Sector | Financials | Health |
52-Week High | $42.86 | $15.38 |
52-Week Low | $16.84 | $11.38 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $6.28B | $10.68B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
Galaxy Digital (GLXY) trades at $19.71, down 0.81% with bearish technical signals but strong analyst support. The company reported Q2 2026 EPS of -$0.09, beating expectations, though revenue declined to $57.4B in 2026 with a net loss of -$315M. Recent news includes a Citigroup upgrade to Buy and upcoming Q3 earnings on October 27, 2026.
Despite current losses, analyst consensus is bullish with an $38.20 price target (81.8% Buy ratings). Key risks include negative profit margins and cash flow challenges, but institutional buying and strategic partnerships provide upside potential if earnings improve.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Galaxy provides digital-asset financial services and data center infrastructure. Its digital-assets business includes trading, asset management, investment banking, staking, tokenization, and custody technology.
Read more on GLXY →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →